Search Results

Nxera Pharma Co., Ltd. is pleased to announce the launch of its new company name, having received approval at the 34th Ordinary General Meeting of Shareholders held on 27 March 2024.

Sosei Group Corporation announces that Idorsia Pharmaceuticals Japan Ltd., a Sosei Group company, has submitted a New Drug Application to the Japanese Pharmaceuticals and Medical Devices Agency for the approval of daridorexant, a dual orexin receptor antagonist which has been co-developed with Mochida Pharmaceutical Co., Ltd., for the treatment of adult patients with insomnia.

Sosei Group Corporation, announces that at a meeting held on 15 February 2024, its Board of Directors resolved to change the corporate names of the Company and its subsidiaries and the location of the head office of the Company.

Meihua International Medical Technologies Co., Ltd., a reputable manufacturer and provider of Class I, II and III disposable medical devices with operating subsidiaries in China, announced that its board of directors has approved and authorized a share repurchase program of up to $3 million of the Company’s outstanding ordinary shares.

Sosei Group Corporation provides an update on operational activities and reports its consolidated results for the 12 months ended 31 December 2023.

Sosei Group Corporation announces that the re-election of its Board of Directors and Executive Officers was approved at the Company’s 34th Annual Shareholders’ Meeting and a subsequent Board of Directors meeting, held in Tokyo.

Rege Nephro CO., Ltd. (https://www.regenephro.co.jp/en) has announced that patient enrollment began in April for the second stage of its Phase II clinical trial of tamibarotene as a developmental product for the treatment of autosomal dominant polycystic kidney disease (ADPKD) under the code RN-014.